ArticleCancer chemotherapy and pharmacology2025
Model-informed development of a cost-saving dosing regimen for enfortumab vedotin.
Catharina Jp Op 't Hoog et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it